An LC-MS/MS method for simultaneous determination of LB-100 and its active metabolite, endothall, in human plasma
We have developed and validated a novel LC-MS/MS method for the simultaneous quantification of LB-100 and its active metabolite, endothall, in human plasma following solid-phase extraction. LB-105 and endothall-D6 were used as internal standards. Chromatographic separation was achieved on a Hypercarb™ column using 5 mM (NH4)2CO3 and 30:70 (v/v) 100 mM (NH4)2CO3:acetonitrile as mobile phases. Detection was performed via positive electrospray ionization mode with multiple reaction monitoring. The assay exhibited linearity in the concentration range of 2.5-500 ng/ml for both analytes. Intra- and inter-assay precision and accuracy were within ±11%. LB-100 and endothall recoveries were 78.7 and 86.7%, respectively. The validated LC-MS/MS method enabled the accurate measurement of LB-100 and endothall in patient samples from an ongoing clinical trial (NCT04560972).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Bioanalysis - 15(2023), 17 vom: 16. Sept., Seite 1095-1107 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Feng, Ye [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
145-73-3 |
|---|
| Anmerkungen: |
Date Completed 18.09.2023 Date Revised 16.11.2023 published: Print-Electronic ClinicalTrials.gov: NCT04560972 Citation Status MEDLINE |
|---|
| doi: |
10.4155/bio-2023-0078 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36083650X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36083650X | ||
| 003 | DE-627 | ||
| 005 | 20231226083850.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/bio-2023-0078 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1202.xml |
| 035 | |a (DE-627)NLM36083650X | ||
| 035 | |a (NLM)37584370 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Feng, Ye |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a An LC-MS/MS method for simultaneous determination of LB-100 and its active metabolite, endothall, in human plasma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.09.2023 | ||
| 500 | |a Date Revised 16.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04560972 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a We have developed and validated a novel LC-MS/MS method for the simultaneous quantification of LB-100 and its active metabolite, endothall, in human plasma following solid-phase extraction. LB-105 and endothall-D6 were used as internal standards. Chromatographic separation was achieved on a Hypercarb™ column using 5 mM (NH4)2CO3 and 30:70 (v/v) 100 mM (NH4)2CO3:acetonitrile as mobile phases. Detection was performed via positive electrospray ionization mode with multiple reaction monitoring. The assay exhibited linearity in the concentration range of 2.5-500 ng/ml for both analytes. Intra- and inter-assay precision and accuracy were within ±11%. LB-100 and endothall recoveries were 78.7 and 86.7%, respectively. The validated LC-MS/MS method enabled the accurate measurement of LB-100 and endothall in patient samples from an ongoing clinical trial (NCT04560972) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a LB-100 | |
| 650 | 4 | |a LC–MS | |
| 650 | 4 | |a chromatography | |
| 650 | 4 | |a endothall | |
| 650 | 4 | |a human plasma | |
| 650 | 4 | |a mass spectrometry | |
| 650 | 4 | |a oncology | |
| 650 | 4 | |a pharmacokinetics | |
| 650 | 4 | |a validation | |
| 650 | 7 | |a LB100 |2 NLM | |
| 650 | 7 | |a endothall |2 NLM | |
| 650 | 7 | |a 145-73-3 |2 NLM | |
| 700 | 1 | |a Massarelli, Erminia |e verfasserin |4 aut | |
| 700 | 1 | |a Forman, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Kovach, John S |e verfasserin |4 aut | |
| 700 | 1 | |a Salgia, Ravi |e verfasserin |4 aut | |
| 700 | 1 | |a Synold, Timothy W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioanalysis |d 2009 |g 15(2023), 17 vom: 16. Sept., Seite 1095-1107 |w (DE-627)NLM196969840 |x 1757-6199 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:17 |g day:16 |g month:09 |g pages:1095-1107 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/bio-2023-0078 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 17 |b 16 |c 09 |h 1095-1107 | ||